End-stage cardiomyopathy because of hereditary hemochromatosis successfully treated with erythrocytapheresis in combination with left ventricular assist device support.

E. Rombout-Sestrienkova, N. de Jonge, K. Martinakova, C. Klopping, K.P.M. van Galen, A. Vink, E.M. Wajon, W.M Smit, C. van Bree, G.H. Koek

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)541-543
Number of pages3
JournalCirculation. Heart Failure
Volume7
Issue number3
DOIs
Publication statusPublished - 2014

Keywords

  • Cardiomyopathies
  • Combined Modality Therapy
  • Cytapheresis
  • Erythrocytes
  • Heart-Assist Devices
  • Hemochromatosis
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Ventricular Dysfunction, Left

Cite this